This site is intended for Healthcare Professionals only.

Cipla gets regulator’s nod to market its COPD drug in US


Share post:

Pharmaceutical company Cipla has received final consent from the US health regulator for Arformoterol Tartrate inhalation solution.

The approved product is used to treat conditions like chronic bronchitis and emphysema in the US market.

The company has received final approval for its abbreviated new drug application (ANDA) for Arformoterol Tartrate inhalation solution 15 mcg/2 mL from the United States Food and Drug Administration (US FDA), Cipla said in a regulatory filing on Wednesday (June 23).

It is a generic version of Sunovion Pharmaceuticals Inc’s Brovana.

Brovana is used in maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Brovana had sales of around $438 million (£314m) in the US for the 12-month period ending April 2021.

The new product is available for shipping immediately, Cipla said.


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

FIP supports PDA’s Safer Pharmacies Charter

PDA urges all UK pharmacists to take part in the 2024 Safer Pharmacies Survey The International Pharmaceutical Federation...

Topiramate should not be prescribed for epilepsy during pregnancy unless…

MHRA tightens safety measures for topiramate by introducing a new pregnancy prevention programme  Healthcare professionals in the UK are...

WHO issues alert on fake copies of Novo Nordisk’s diabetes drug Ozempic

Falsified batches of Ozempic (semaglutide) were detected in Brazil, the UK, Northern Ireland and the United States The...

Synnovis cyber attack: NHS patient data leaked, services impacted

The NHS has set up helpline number to answer queries and concerns about patient data as Synnovis cyber...